Oncternal Therapeutics (ONCT) Insider Trading & Ownership $1.16 +0.02 (+1.75%) (As of 12:50 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Oncternal Therapeutics (NASDAQ:ONCT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage11.20%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$92,735.84Number OfInsiders Selling(Last 12 Months)0 Get ONCT Insider Trade Alerts Want to know when executives and insiders are buying or selling Oncternal Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ONCT Insider Buying and Selling by Quarter Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Oncternal Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails4/8/2024Robert James WillsDirectorBuy3,086$8.96$27,650.56 3/28/2024Robert James WillsDirectorBuy6,914$8.48$58,630.72 2/23/2024David F HaleDirectorBuy714$9.04$6,454.56 (Data available from 1/1/2013 forward) ONCT Insider Trading Activity - Frequently Asked Questions Who is on Oncternal Therapeutics's Insider Roster? The list of insiders at Oncternal Therapeutics includes Chase C Leavitt, David F Hale, Gunnar F Kaufmann, James B Breitmeyer, Richard G Vincent, Robert James Wills, and Salim Yazji. Learn more on insiders at ONCT. What percentage of Oncternal Therapeutics stock is owned by insiders? 11.20% of Oncternal Therapeutics stock is owned by insiders. Learn more on ONCT's insider holdings. Which Oncternal Therapeutics insiders have been buying company stock? The following insiders have purchased ONCT shares in the last 24 months: Chase C Leavitt ($4,350.00), David F Hale ($6,454.56), Gunnar F Kaufmann ($9,830.00), James B Breitmeyer ($29,000.00), Richard G Vincent ($9,000.00), Robert James Wills ($86,281.28), and Salim Yazji ($4,300.00). How much insider buying is happening at Oncternal Therapeutics? Insiders have purchased a total of 20,114 ONCT shares in the last 24 months for a total of $149,215.84 bought. Oncternal Therapeutics Key ExecutivesDr. James B. Breitmeyer M.D. (Age 70)Ph.D., President, CEO & Director Compensation: $881.36kMr. Richard G. Vincent CPA (Age 60)CFO & Treasurer Compensation: $602.84kDr. Salim Yazji M.D. (Age 55)Chief Medical Officer Compensation: $648.53kDr. Rajesh Krishnan Ph.D. (Age 51)Chief Technical & Scientific Officer Mr. Chase C. Leavitt (Age 42)General Counsel & Secretary Mr. Pablo UrbanejaSenior Vice President of Corporate DevelopmentMs. Anita WisethSenior Vice President of Human Resources More Insider Trading Tools from MarketBeat Related Companies AIM Insider Trades BGXX Insider Trades SNSE Insider Trades TLPH Insider Trades NKGN Insider Trades AWH Insider Trades CDT Insider Trades TSBX Insider Trades INDP Insider Trades MBIO Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:ONCT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncternal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
